for Journals by Title or ISSN
for Articles by Keywords
Journal Cover PharmAsia News
  [1 followers]  Follow
   Full-text available via subscription Subscription journal
   ISSN (Print) 1875-7774
   This journal is no longer being updated because:
    The journal ceased publication
  • Commercial Model Innovation Key To Lowering China Compliance Risks
    • Abstract: Balanced scorecards, big data, and platform strategies are among the new tools being employed by pharma companies ramping up compliance and lowering risks in China, where market access remains challenging and pricing pressures persistent. Such commercial model innovation should also improve physician interaction while providing new medical solutions, said executives at a recent RDPAC gathering in Beijing.
      PubDate: Thu, 07 Jul 2016 09:35:01 -040
  • Bridge Bio Eyes Faster Pipeline Progress Through New Funds, Model
    • Abstract: A Series A funding for South Korean bioventure Bridge Biotherapeutics may encourage creation of “no research, development only” bioventures and early investments in the biotech sector.
      PubDate: Thu, 07 Jul 2016 09:15:02 -040
  • Spotlight Back On Indian Rotavirus Vaccine Controversy
    • Abstract: A public interest litigation has sought to revive efforts to access segregated trial data from a locally developed oral rotavirus vaccine in India, amid concerns that it might be associated with a higher risk of intussusception in certain pockets of the country. In a further dimension, an expert panel recently brought up a "representation" on the inclusion of intussusception in the vaccine's package insert.
      PubDate: Thu, 07 Jul 2016 09:10:00 -040
  • Sovaldi Among New HCV Drugs In Turkey Reimbursement Pact
    • Abstract: Turkey’s public health payer has added three new hepatitis C drugs to the reimbursement list through a special deal with manufacturers, although the price the SGK will be paying to the companies is not being revealed.
      PubDate: Thu, 07 Jul 2016 03:10:02 -040
  • INTERVIEW: Ex-Advinus CEO’s Bittersweet Journey
    • Abstract: Life appears to have come full circle for Advinus Therapeutics' co-founder and former CEO and managing director, Dr. Rashmi Barbhaiya, who recently moved back to the US from India.
      PubDate: Wed, 06 Jul 2016 21:40:01 -040
  • Genexine Raises New Funds To Progress Promising HPV, Other Projects
    • Abstract: South Korean bioventure Genexine is on track to meet its goal of progressing and expanding this year the clinical development of its leading assets - orphan disease drugs and cancer immunotherapies. The company now plans to raise new funds via share and bond issues to domestic and overseas investors including its Chinese strategic alliance partner Tasly.
      PubDate: Wed, 06 Jul 2016 20:55:01 -040
  • Record CStone Funding Heralds New Era For China Startups
    • Abstract: With $150m in hand and a pipeline covering five therapeutic areas, CStone has already broken the record for the largest Series A investment in a Chinese biopharma startup. If that's not impressive enough, add a CEO from big pharma and support from China’s largest CRO.
      PubDate: Wed, 06 Jul 2016 03:55:02 -040
  • Will Turkey’s Strong Biotech Development Steps Be Effective'
    • Abstract: The Turkish market for biotech drugs and biologics is growing strongly but most are imported and the country is now determined to develop its infrastructure for local manufacturing through a series of moves. While there has been some progress, it is not yet certain if this is enough to meet high official expectations and convince investors.
      PubDate: Wed, 06 Jul 2016 01:45:00 -040
  • TiGenix The Latest Partner In Takeda Deal Frenzy
    • Abstract: The latest in a non-stop succession of deals over the past few weeks for Takeda sees the Japanese major add a late-stage TiGenix asset to its GI care portfolio, with Europe to be the initial focus of the tie-up.
      PubDate: Wed, 06 Jul 2016 00:40:00 -040
  • Eisai Parades Pipeline Before Investors During First US R&D Day
    • Abstract: Management highlighted Eisai’s neurology and oncology assets during a Scientific Day in New York, the first formal R&D briefing the Japanese pharma’s US subsidiary has held in more than 20 years operating in the country.
      PubDate: Tue, 05 Jul 2016 20:00:00 -040
  • Fast And Furious: Lessons From China FDA's Innovation Push
    • Abstract: One year after the China FDA dashed out a flurry of policies to encourage innovative new drugs, a regulatory affairs veteran sheds light on how the policies are being implemented in practice and what lessons have been learned.
      PubDate: Tue, 05 Jul 2016 03:00:17 -040
  • Japan Grants Global First Nod For Brodalumab, For Psoriasis
    • Abstract: Japan has granted the first approval worldwide for brodalumab as a biologic therapy for psoriasis, one of two new antibody therapies for the disorder in a new batch of approvals that also included Praluent and Kyprolis.
      PubDate: Tue, 05 Jul 2016 02:05:00 -040
  • Share Fillip As Indian Pharma Crests US Regulatory Hump
    • Abstract: For the last few years, Indian generic companies have been making headlines for all the wrong reasons, rapped by the US Food and Drug Administration over problems ranging from fudged test results to poor-quality manufacturing standards. But lately, the firms have been enjoying a run of good regulatory tidings, giving a fillip to their share prices.
      PubDate: Mon, 04 Jul 2016 21:15:00 -040
  • New R&D Tax Incentives Enough To Support Korean Drug
    • Abstract: The South Korean government has unveiled more details of new R&D tax support for emerging industries, including bio-health care, to encourage research spending by the pharma sector. But a local industry association suggests the government may also have to think twice about an existing R&D tax incentive system that provides incremental reductions and gives preferential benefits to smaller firms.
      PubDate: Mon, 04 Jul 2016 02:15:02 -040
  • Takeda Gets GI Candidate – And Possibly Company – In Altos
    • Abstract: In the latest in a string of deals, Takeda's agreement to acquire global rights to Altos's gastroparesis candidate - and possibly the company itself - gives the Japanese giant another asset in its core gastrointestinal area.
      PubDate: Mon, 04 Jul 2016 00:55:01 -040
  • New Takeda India Leadership Amid Realignment
    • Abstract: Whether or not it's a rejig in the normal course of business isn't very clear, but Japanese pharma giant Takeda has "realigned" certain teams as it pursues plans to provide sustainable access to its medicines under a new leadership in India.
      PubDate: Sun, 03 Jul 2016 21:15:01 -040
  • For Astellas SVP, Company’s Cancer Care Prize Is Personal
    • Abstract: Astellas has $100,000 that it wants to give to people or groups with good ideas for improving cancer care via the company's C3 Prize. Senior Vice President Mark Reisenauer has a very personal perspective on the initiative after recently losing his father to head and neck cancer.
      PubDate: Fri, 01 Jul 2016 02:00:01 -040
  • Biocon, Quark Win Pioneering Indian Nod For RNAi Eye Therapy Trial
    • Abstract: Asia’s biggest biotech company, India’s Biocon Ltd, has announced it will conduct what it says is the first-ever clinical trial of a siRNA therapy in India with US partner Quark, is aimed at tackling a rare eye condition.
      PubDate: Thu, 30 Jun 2016 22:15:03 -040
  • Letter From The Editor: Important Information On PharmAsia News
    • Abstract: PharmAsia News (PAN) has always aimed to bring high-value, original and analytical coverage of the Asia-Pacific pharma markets to our readers, and this unique and differentiated content - and much more - will continue to be available under exciting changes that will expand the breadth of information you receive as a subscriber.
      PubDate: Thu, 30 Jun 2016 20:45:00 -040
  • Strong Biopharma Appetite Aids Solid Korean IPO Debuts
    • Abstract: Shares of Green Cross LabCell and ST Pharm jumped on their debut following their successful initial public offerings earlier this month. Numerous South Korean biotechs are seeking IPOs this year amid the government's ongoing drive to nurture the biopharma sector and the stock exchange's efforts to ease listing regulations to help fund raising by promising small firms including bioventures.
      PubDate: Thu, 30 Jun 2016 02:05:00 -040
  • Hangzhou’s Attractions Play Big Part In New Pfizer China Investment
    • Abstract: The Hangzhou Economic Development Area has become a highly attractive spot for global pharmas to establish an expanded presence in China, as its integrated platforms, high quality talent pool and incentives help develop a powerhouse of high-end manufacturing. Pfizer’s $350m decision to join the industrial cluster for a new biotech center follows on from others including MSD, Lilly and Bayer.
      PubDate: Thu, 30 Jun 2016 01:25:01 -040
  • Limited Japan Nod For Cytori’s Osteoarthritis Cell Therapy
    • Abstract: Japan's well-defined regulatory framework for cell and regenerative therapies has notched up another "win" with the limited-use approval of a product for knee osteoarthritis, which should also generate useful new revenues for originator Cytori.
      PubDate: Wed, 29 Jun 2016 22:50:02 -040
  • India To Overhaul Old Drug Law To Cover Medical Advances
    • Abstract: Prime Minister Narendra Modi’s government has decided to "comprehensively review" India's antiquated drug legislation to take into account the latest medical developments and improve safety, amid complaints about poor-quality manufacturing and products.
      PubDate: Wed, 29 Jun 2016 21:15:01 -040
  • Delays As Korea Grapples With Immuno-Oncology Drug Coverage
    • Abstract: With some of the new immuno-oncology drugs have already been launched in South Korea, experts are emphasizing the need to rapidly reimburse the innovative and pricey cancer therapies to reduce patients’ financial burden, amid debate over the best way of calculating prices.
      PubDate: Wed, 29 Jun 2016 00:50:01 -040
  • India Liberalizes Foreign Investments But Will Money Flow'
    • Abstract: Following the easing of India’s foreign direct investment norms in the pharmaceutical sector, reforms are expected to buoy foreign capital inflows and investor sentiment, especially private equity, though some opponents claim it may potentially have a dire impact on India's future medicines security.
      PubDate: Tue, 28 Jun 2016 22:25:02 -040
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
Home (Search)
Subjects A-Z
Publishers A-Z
Your IP address:
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-